Prime Editing

Prime editing is a next-generation genome editing technology that rewrites DNA without making double-strand breaks — the dangerous cuts that traditional CRISPR-Cas9 requires. Invented by David Liu at the Broad Institute in 2019, prime editing uses a modified Cas9 fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit. This "search-and-replace" mechanism can make all 12 types of point mutations, small insertions, and small deletions with high precision.

The most significant recent advance is disease-agnostic treatment via suppressor tRNAs. Published in Nature (November 2025), Liu's team demonstrated that prime editing can install suppressor tRNA genes that read through premature stop codons (nonsense mutations). This is transformative because nonsense mutations cause approximately 30% of all rare genetic diseases — roughly 11% of all known pathogenic mutations. Rather than designing a unique therapeutic for each disease, a single suppressor tRNA approach could address thousands of conditions with the same molecular tool.

Error rates have improved dramatically. Early suppressor tRNA approaches suffered from 1-in-7 misincorporation rates at normal stop codons (where the cell intentionally stops translation). The latest work has reduced this to 1-in-101 — a 14-fold improvement that brings the approach closer to clinical viability. The system must distinguish between premature stop codons (disease-causing) and normal stop codons (essential for proper protein termination).

Key Claims

• Suppressor tRNAs address ~30% of rare diseases — Nonsense mutations cause ~11% of all pathogenic variants, affecting ~30% of rare disease patients. A single tRNA-based approach could treat thousands of conditions. Evidence: strong (Prime Editing Suppressor tRNAs)
• Error rates improved from 1-in-7 to 1-in-101 — Misincorporation at normal stop codons reduced 14-fold, critical for clinical safety. Evidence: strong (Prime Editing Suppressor tRNAs)
• No double-strand breaks — Prime editing avoids the insertions/deletions (indels) and chromosomal rearrangements associated with traditional CRISPR cuts. Evidence: strong (Prime Editing Suppressor tRNAs)
• 19 clinical trials underway — Base editing and prime editing trials active across 5 countries as of late 2025. Evidence: strong (Prime Editing Suppressor tRNAs)

Benchmarks & Data

• 1-in-101 misincorporation rate at normal stop codons (vs. 1-in-7 previously)
• ~30% of rare diseases caused by nonsense mutations (targetable by suppressor tRNAs)
• 19 clinical trials using base/prime editing across 5 countries
• First FDA-approved prime editing trial began April 2024

Open Questions

• Can suppressor tRNA expression be precisely controlled to avoid readthrough at normal stop codons in vivo?
• What is the long-term durability of prime-edited corrections in different tissue types?
• How will delivery beyond the liver (currently the easiest target) be solved for systemic diseases?
• What regulatory pathway will disease-agnostic therapies follow — per-disease approval or platform approval?
• Can manufacturing costs decrease enough for rare disease economics to work?

Related Concepts

• Epigenetic Editing — Alternative no-cut approach using methylation changes
• CRISPR Clinical Translation — Clinical trial landscape for gene editing
• Gene Therapy Delivery — The delivery bottleneck constraining all gene therapies

Backlinks

Pages that reference this concept:

• Prime Editing Suppressor tRNAs